Lobbying

Merck Sharp & Dohme's latest lobbying report covers Q2 2026, at $80K. The four quarters Q4 2025–Q3 2026 total $240K. Its first report covers Q3 2025; the issues it reports most are Pharmacy and Miscellaneous Tariff Bills.

Merck Sharp & Dohme

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$240K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q3 2025
The first quarter a report named it

Lobbying by quarter

Merck Sharp & Dohme lobbying by quarter
Merck Sharp & Dohme lobbying by quarter
QuarterAmountReports
Q3 2025$80K1
Q4 2025$80K1
Q1 2026$80K1
Q2 2026$80K1
Q3 2026$00

By issue

  • Pharmacy$40K · 1 reports
  • Tariffs$40K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

No house or agency named.

Firms it paid

Firm
Ballard Partners$320K4 quarters

Former officials lobbying for it

Former position
ALISON ANWAYLA to Senator Pat Roberts 2006-2010Q3 2025
HUNTER MORGENPolicy Advisor, Office of Policy Planning, U.S. State Dept. (2017); Deputy Director, Office of Trade & Manufacturing Policy, WH (2017-2018); Special Assistant to the President, Office of the Senior Advisor for Policy, WH (2018-2020)Q3 2025

Lobbying reports

Filed by
07/17for Q2Ballard Partners$80K
04/16for Q1Ballard Partners$80K
01/14for Q4 2025Ballard Partners$80K
25/10/17for Q3 2025Ballard Partners$80K
25/10/16for Q3 2025Ballard Partners$50K
25/09/02for Q3 2025Ballard PartnersUnder $5,000